Delta tocotrienol in recurrent ovarian cancer. A phase II trial
نویسندگان
چکیده
منابع مشابه
A randomized phase II selection trial in patients with advanced/recurrent gastric cancer: Trial for Advanced Stomach Cancer (TASC).
A randomized phase II clinical trial is being conducted for patients with advanced or recurrent gastric cancer, in order to select the most promising treatment for subsequent evaluation in a large-scale phase III trial. We compare four chemotherapeutic treatments, which include two sequential and two combination regimens using paclitaxel with 5-fluorouracil or S-1, an oral fluorouracil derivati...
متن کاملResponse to neoadjuvant chemotherapy in locally advanced gastric and gastroesophageal cancer: Phase II clinical trial
Background: Gastric cancer is an important health problem across the world. Chemotherapy in combination with local treatment is standard treatment for locally advanced gastroesophageal cancers. The purpose of this investigation was evaluation of response and tolerability to neoadjuvant EOX regimen in locoregionally advanced gastric cancer. Materials and Methods: patients with locoregionally adv...
متن کاملPegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial.
BACKGROUND The GINECO group previously demonstrated that pegylated liposomal doxorubicin (PLD)-carboplatin combination was an effective and well-tolerated treatment for advanced ovarian cancer (AOC) patients in late relapse. The purpose of the present analysis was to confirm these results in a prospective cohort of late-relapsing AOC patients. PATIENTS AND METHODS Eighty-one consecutive patie...
متن کاملA phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.
PURPOSE To evaluate study feasibility, toxicity, drug concentrations, and activity of escalating doses of the synthetic retinoid fenretinide [N-(4-hydroxyphenyl)retinamide (4-HPR)] in ovarian cancer by measuring serum CA125 and cytomorphometric biomarkers in cancer cells collected from ascitic fluid before and after treatment. METHODS Twenty-two naive patients with ascitic ovarian cancer were...
متن کاملA phase II trial of voreloxin in women with platinum-resistant ovarian cancer.
5559 Background: Voreloxin is a naphthyridine analog that intercalates DNA and inhibits topoisomerase II, inducing apoptosis. Clinical activity has been observed in ovarian cancer and AML. Results are reported from a fully enrolled phase II study of 3 dose levels of single agent voreloxin in patients (pts) with 1° or 2° platinum-resistant or refractory ovarian cancer. METHODS Pts may have rec...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pharmacological Research
سال: 2019
ISSN: 1043-6618
DOI: 10.1016/j.phrs.2019.01.017